Douglas A Treco bought $1.1M of CRISPR Therapeutics AG (CRSP)
Executed Aug 6 2025, disclosed Aug 8 2025, 2 days later.
Over the 21 trading sessions from the disclosed entry session (Aug 8 2025), the stock returned -3.8% (delay-adjusted); from the execution session (Aug 6 2025), -5.1%. Derived: entry at the session's open, exit at the close 20 sessions later.
Douglas A Treco (Director) filed 1 Form 4 report in the past 24 months (1 purchase, 0 sales), most often in CRISPR Therapeutics AG (CRSP). Across 1 priced purchase filing, the average 21-session return was -5.1% from execution and -3.8% from disclosure (delay-adjusted; derived). The largest single filing was $1.1M of CRSP (20,000 sh × $57.03, as filed), executed Aug 6 2025.
Healthcare · CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered R…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→